First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM
- PMID: 21807978
- PMCID: PMC3186983
- DOI: 10.1128/AAC.00341-11
First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM
Abstract
Achromobacter xylosoxidans is an emerging pathogen in cystic fibrosis patients. The multidrug resistance of these bacteria remains poorly understood. We have characterized in a clinical strain the first resistance-nodulation-cell division (RND)-type multidrug efflux pump in this species: AxyABM. The inactivation of the transporter component axyB gene led to decreased MICs of cephalosporins (except cefepime), aztreonam, nalidixic acid, fluoroquinolones, and chloramphenicol.
Figures

Similar articles
-
Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.Antimicrob Agents Chemother. 2013 Jan;57(1):603-5. doi: 10.1128/AAC.01243-12. Epub 2012 Oct 22. Antimicrob Agents Chemother. 2013. PMID: 23089757 Free PMC article.
-
Role of AxyABM overexpression in acquired resistance in Achromobacter xylosoxidans.J Antimicrob Chemother. 2022 Mar 31;77(4):926-929. doi: 10.1093/jac/dkab479. J Antimicrob Chemother. 2022. PMID: 35029278
-
Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome.BMC Microbiol. 2006 Jul 20;6:66. doi: 10.1186/1471-2180-6-66. BMC Microbiol. 2006. PMID: 16857052 Free PMC article.
-
[The role of cell wall organization and active efflux pump systems in multidrug resistance of bacteria].Mikrobiyol Bul. 2007 Apr;41(2):309-27. Mikrobiyol Bul. 2007. PMID: 17682720 Review. Turkish.
-
Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature.BMC Microbiol. 2016 Jun 24;16(1):122. doi: 10.1186/s12866-016-0736-1. BMC Microbiol. 2016. PMID: 27342812 Free PMC article. Review.
Cited by
-
Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes.PLoS One. 2013 Jul 22;8(7):e68484. doi: 10.1371/journal.pone.0068484. Print 2013. PLoS One. 2013. PMID: 23894309 Free PMC article.
-
AMRrounds: Achromobacter xylosoxidans susceptibility-so it goes.JAC Antimicrob Resist. 2024 Sep 20;6(5):dlae134. doi: 10.1093/jacamr/dlae134. eCollection 2024 Oct. JAC Antimicrob Resist. 2024. PMID: 40248054 Free PMC article. No abstract available.
-
Hospital Acquired Pneumonia Due to Achromobacter spp. in a Geriatric Ward in China: Clinical Characteristic, Genome Variability, Biofilm Production, Antibiotic Resistance and Integron in Isolated Strains.Front Microbiol. 2016 May 9;7:621. doi: 10.3389/fmicb.2016.00621. eCollection 2016. Front Microbiol. 2016. PMID: 27242678 Free PMC article.
-
Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans.Sci Rep. 2018 May 25;8(1):8181. doi: 10.1038/s41598-018-26079-z. Sci Rep. 2018. PMID: 29802257 Free PMC article.
-
Genomic characterization of Achromobacter species isolates from chronic and occasional lung infection in cystic fibrosis patients.Microb Genom. 2021 Jul;7(7):000606. doi: 10.1099/mgen.0.000606. Microb Genom. 2021. PMID: 34292148 Free PMC article.
References
-
- Aisenberg G., Rolston K. V., Safdar A. 2004. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989–2003). Cancer 101:2134–2140 - PubMed
-
- Almuzara M., et al. 2010. In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. Int. J. Antimicrob. Agents 35:68–71 - PubMed
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources